The quality of evidence to support the use of deep venous stenting to treat obstructive CVD is currently weak. The treatment does however appear promising and is safe and should therefore be considered as a treatment option while the evidence base is improved.

This study was supported by a research grant from the Clarivein  device manufacturer, Vascular Insights and an educational research grant from the Graham-Dixon Charitable Trust. Vascular Insights provided funding for Clarivein  devices, patient follow-up and duplex ultrasonography. Case funding was not used in this study. All trial particulars (design, data collection, analysis, discussion and data access) were performed independently of the funding bodies and the trial's research sponsor was Imperial College London.